Results 1 to 10 of about 248 (96)

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis [PDF]

Trials, 2023
Background Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a
A Dierig, M Hoelscher, S Schultz, L Hoffmann, A Jarchow-MacDonald, EM Svensson, L Te Brake, R Aarnoutse, M Boeree, TD McHugh, LM Wildner, X Gong, PPJ Phillips, LT Minja, N Ntinginya, S Mpagama, A Liyoyo, RS Wallis, M Sebe, FA Mhimbira, B Mbeya, M Rassool, L Geiter, YL Cho, N Heinrich   +24 more
doaj   +4 more sources

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China [PDF]

Frontiers in Medicine, 2022
ObjectiveTo investigate the in vitro activities of five oxazolidinones in parallel against the reference strains of different mycobacterial species and clinical isolates of Mycobacterium tuberculosis (Mtb), and shed light on the differences in the ...
Chenqian Wang, Chenqian Wang, Guirong Wang, Fengmin Huo, Yi Xue, Junnan Jia, Lingling Dong, Liping Zhao, Fen Wang, Hairong Huang, Hongfei Duan   +10 more
doaj   +2 more sources

Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection [PDF]

Scientific Reports, 2023
The prevalence of Mycobacterium avium complex-pulmonary disease (MAC-PD) has become a growing concern worldwide, and current treatments involving macrolides (clarithromycin [CLR] or azithromycin), ethambutol, and rifampicin have limited success ...
Ju Mi Lee, Lee-Han Kim, Su-Young Kim, Byung Woo Jhun, Wonsik Lee, Sung Jae Shin   +5 more
doaj   +2 more sources

Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis. [PDF]

Antimicrob Agents Chemother, 2022
Delpazolid, an oxazolidinone, has been studied in non-clinical studies of efficacy and toxicity and Phase 1 clinical studies. Delpazolid has in vitro activity against Gram-positive bacteria, including Mycobacterium tuberculosis.
Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, Kim SK, Kim SJ, Kang YS, Kim TH, Mok J, Byun MK, Park HJ, Joh JS, Park YB, Lim HS, Choi H, Lee SH, Kim H, Yang J, Kim H, Shen X, Alsultan A, Cho I, Geiter L, Shim TS.   +25 more
europepmc   +3 more sources

The pipeline of new molecules and regimens against drug-resistant tuberculosis [PDF]

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021
The clinical development and regulatory approval of bedaquiline, delamanid and pretomanid over the last decade brought about significant progress in the management of drug-resistant tuberculosis, providing all-oral regimens with favorable safety profiles.
Todd A. Black, Ulrike K. Buchwald
doaj   +2 more sources

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. [PDF]

J Antimicrob Chemother
Funding: This study was conducted by the PanACEA consortium, funded by the EDCTP2 programme (grant number TRIA2015-1102) with support from the German Ministry for Education and Research (BMBF; 01KA1701); further funding was contributed by the German ...
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium .   +28 more
europepmc   +3 more sources

New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? [PDF]

Pharmaceutics
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity.
Ricky Hao Chen, Andrew Burke, Jin-Gun Cho, Jan-Willem Alffenaar, Lina Davies Forsman   +4 more
doaj   +2 more sources

In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China [PDF]

Infection and Drug Resistance, 2021
Xia Yu,* Fengmin Huo,* Fen Wang,* Shu’an Wen, Guanglu Jiang, Yi Xue, Lingling Dong, Liping Zhao, Rui Zhu, Hairong Huang National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Yu X, Huo F, Wang F, Wen S, Jiang G, Xue Y, Dong L, Zhao L, Zhu R, Huang H   +9 more
doaj   +2 more sources

Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects [PDF]

Molecules, 2021
This review covers the main aspects concerning the chemistry, the biological activity and the analytical determination of oxazolidinones, the only new class of synthetic antibiotics advanced in clinical use over the past 50 years.
Claudia Foti, Anna Piperno, Angela Scala, Ottavia Giuffrè   +3 more
doaj   +2 more sources

Treatment-shortening regimens for tuberculosis: updates and future priorities. [PDF]

Breathe (Sheff), 2023
In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and ...
Saluzzo F, Adepoju VA, Duarte R, Lange C, Phillips PPJ.   +4 more
europepmc   +4 more sources